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As the country with the largest number of infected individuals 
in the world, South Africa (SA) is at the epicentre of the human 
immunodeficiency virus (HIV) epidemic. In 2008 there were 5.7 
million people living with HIV in SA, accounting for 18% of the 
global total, i.e. 1 in 6 people living with HIV in the world today 
lives in SA. This is in contrast to SA’s population size, which is just 
0.7% of the world’s total population.1 History has taught us that 
the way to eradicate a global viral epidemic is to design, mass-
produce, and then systematically vaccinate the population at risk 
with an effective prophylactic vaccine. Diseases such as smallpox 
in humans and rinderpest in cattle have been eradicated, and other 
diseases such as poliomyelitis and tetanus are now rare as a result 
of vaccination.2 Recently, rotavirus vaccination has had a large 
impact on reducing infant mortality.3 Therefore, it is appropriate 
that a long-term goal of HIV control programmes should include 
the development of a prophylactic HIV vaccine. However, the past 
has also shown us that this path to a ‘silver bullet’ may be a long and 
complicated one.
In 2009 the University of Cape Town (UCT) announced that 
2 candidate prophylactic HIV vaccines, that were designed and 
developed at the university, had entered phase 1 clinical trials.4 This 
article describes the history of HIV vaccine research at UCT, and the 
partnerships that made the project possible. 
Challenges in HIV vaccine development
HIV is a highly variable virus, with the sequence diversity in one 
person being equivalent to that seen in an influenza outbreak in a 
whole country in 1 year.5 Given that new combinations of influenza 
vaccines are potentially needed each year, this poses a major challenge 
to the development of an HIV vaccine or vaccines. In addition, 
animal models for HIV provide useful information but are not 
perfect: the positive results seen in rhesus macaques with simian 
immunodeficiency virus (SIV)/simian/human immunodeficiency 
virus (SHIV) vaccines in terms of protection from challenge have not 
been translated into human clinical trials. There is therefore a limited 
understanding of the correlates of protection needed to design an 
HIV vaccine. In the recent past, HIV vaccines have been designed to 
induce either good antibody responses or T-cell responses. However, 
it is likely that an effective prophylactic vaccine will have to induce 
both types of response: antibody responses are desirable in order to 
prevent infection, and a good T-cell response to remove infected cells 
before infection is established is also desirable. A strong early T-cell 
response should also impact on establishment of the HIV set point if 
the infection is not eliminated, resulting in slower progression to AIDS.
Indications that a vaccine could work
To date candidate HIV vaccines have been tested in 3 human 
efficacy (phase 3) clinical trials. Both the first trial, based on an 
HIV-1 subtype B envelope protein, and the second trial, based on 
an adenovirus vector expressing HIV-1 sub-type B Gag, Pol, and 
Nef proteins, gave no protection from HIV infection. The third 
trial – RV144, performed in Thailand – gave 60% protection (post 
hoc analysis) from HIV infection 1 year after vaccination, and 31.2% 
at the end of 3.5 years.6 This vaccine is a combination of envelope 
protein (subtype B and E) and a canary poxvirus vector (ALVAC-
HIV), expressing HIV-1 subtype B protease and Gag, and a fusion 
subtype E and B envelope. Despite the partial success of the RV144 
trial, the correlates of protection have not been easy to establish, and 
research in this direction is still ongoing. It is likely that protection 
was antibody-based, but not related to neutralising antibodies.
Requirements for a vaccine programme
Vaccine development requires a multidisciplinary team of people to 
enable the network required to get the vaccine from early concept 
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development into clinical trials (Fig. 1). The time-lines for product 
development are up to 10 years from concept to manufacturing of 
the vaccine. Resources are needed to keep all components of the 
network functioning along with a good management structure. It is 
fortunate that in SA there is a well-developed regulatory framework, 
as illustrated in Fig. 2. The UCT Vaccine Development Group 
was involved in the early part of the vaccine pipeline, as well as in 
producing preclinical data needed for the regulatory bodies (the Food 
and Drug Administration (FDA), USA, and the Medicines Control 
Council (MCC), SA). The clinical sites developed both through 
national funding via the South African AIDS Vaccine Initiative 
(SAAVI) and international funding, such as the National Institutes 
of Health (NIH)-funded HIV Vaccine Trials Network (HVTN) and 
the multinational International AIDS Vaccine Initiative (IAVI), were 
responsible for providing internationally accredited clinical trial sites 
capable of conducting HIV vaccine trials, from earliest phase through 
to efficacy, to the highest international standards.
UCT HIV Vaccine Development Group
In 2000 a UCT-based consortium was awarded funds by SAAVI 
for the development of HIV-1 subtype C vaccines for SA. The UCT 
Vaccine Development Group’s expertise and previous experience in 
the development of DNA vaccines, subunit vaccines, poxvirus- and 
Bacillus Calmette-Guérin (BCG)-based vaccines formed the core of the 
programme. The group built on this expertise to develop candidate HIV 
vaccines and to test different prime-boost combinations in non-human 
primate models. This enabled the development of considerable HIV 
immunology expertise within the group. SAAVI was reviewed regularly by 
a distinguished panel of international experts, who advised in 2001 that 2 
of the promising candidate vaccines from the UCT programme be selected 
and fast-tracked to human clinical 
trial. The programme was then 
divided into project teams, some for 
the development of these 2 vaccines 
for clinical trial and others for the early 
pipeline vaccine development projects.
Circulating HIV-1 subtypes: 
characterisation
Research on virus characterisation 
in SA had its beginnings in Carolyn 
Williamson’s group in the late 1990s, 
with the finding that men who have 
sex with men were predominantly 
infected with the HIV-1 subtype B 
virus, the main circulating virus in 
Europe and the USA. In contrast, 
the local heterosexual epidemic was 
mainly HIV-1 subtype C, which 
reflected the dominant virus subtypes 
in neighbouring SADC countries. 
The extent of diversity in HIV made 
it important to identify the subtypes 
circulating in the heterosexual 
epidemic before designing vaccines 
for the region. A study of recently 
transmitted viruses in KwaZulu-
Natal indicated that these were 
overwhelmingly HIV-1 subtype 
C. Several isolates were selected on 
which to base an HIV vaccine; criteria 
for selection included isolation of the 
virus within a year of transmission, 
the ability of the virus to grow in 
cell culture, the full genome sequence 
of the virus and the availability of 
serum. To reduce the difference 
between the vaccine immunogen and 
the circulating viruses, a virus isolate 
selected for the vaccine was closest 
to the consensus sequence for local 
subtype C viruses.7
Early pipeline HIV-1 subtype 
C vaccines
Researchers at UCT have a history 
of developing novel viral vaccine 
Fig. 1. The time-line for vaccine development and the network required to get the vaccine from early concept 
development into clinical trials (cGMP = current good manufacturing practice).
Fig. 2. The regulatory process for moving vaccines from vaccine concept into clinical trials. GMO = genetically 
modified organism.
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concepts, as illustrated by their work on the BCG vaccine (the 
vaccine against tuberculosis), expressing papillomavirus or rotavirus 
proteins, as well as the extensive plant and insect cell production of 
subunit vaccines and poxvirus-based vaccines. 
Strategies were thus devised to construct novel HIV candidate 
vaccines based on local HIV isolates. Table 1 gives a summary of 
the candidate HIV vaccines developed at UCT. The vaccines were 
produced in the laboratory, and after quality assessment, candidates 
were selected for preliminary immunogenicity testing in mice. Vaccine 
regimens involved heterologous prime-boost combinations, as this 
has been shown to result in better T-cell responses to HIV compared 
with homologous prime-boost strategies.8 Antibody responses were 
also monitored. After demonstrating adequate immune response in 
mice, the vaccines were tested in non-human primates at the Medical 
Research Council (MRC) non-human primate facility, given the far 
closer genetic relationship between primates and humans. (The MRC 
has for many years had a non-human primate facility which, in the 
early years, included baboons, because of availability; more recently 
rhesus macaques became available after SAAVI purchased a breeding 
colony. This facility is an extremely valuable resource for HIV and 
other vaccine research in SA.)
A number of other novel platforms were established for the 
production of subunit vaccines, including tobacco19 and recombinant 
baculovirus/insect cell platforms.12 Development of plant-based 
subunit vaccines, although successful, was stopped as a result of low 
yields, and replaced with insect cell produced virus-like particle vaccine 
candidates (VLPs). The group investigated fusion proteins based on 
Gag,14 and subsequently the optimising of production parameters and 
testing of immunogenicity of Gag-RT and Gag-Tat-Nef fusion VLPs.15 
Novel HIV vaccine vectors were also explored, with an enhanced 
experimental DNA vaccine for HIV being made that utilises an 
expression enhancer derived from an animal circovirus.16 A novel 
HIV vaccine was made based on the cattle lumpy skin disease 
capripoxvirus vaccine.17 BCG was investigated as a vaccine vector, 
and induced good priming immune responses in mice and non-
human primates.15 Salmonella was tested as an HIV vaccine vector 
in mice.18 HIV VLPs were particularly successful at boosting HIV 
immune responses in baboons induced by priming with either DNA 
vaccines11 or BCG-based vaccines.13
Vaccines for clinical trial
Two HIV vaccines, designated SAAVI DNA-C2 and SAAVI MVA-C, 
were deemed suitable for human clinical trials. This was a challenging 
project, because of cost and relative local inexperience in HIV vaccine 
development. The project was done in close partnership with the 
NIH in the USA. The NIH funded important components of the 
programme, including manufacture and toxicity testing of both 
vaccines in the USA, as capacity was not available in SA. Vaccines 
needed to be manufactured according to current good manufacturing 
practice (GMP) principles, with demonstrably limited toxicity in 
rabbit tests. The NIH also funded the regulatory documentation, a 
vital part of the approval process. Significant mentoring from people 
at the NIH enabled the programme to move forward and to build 
local capacity to support HIV vaccine development. Finally, the 
HVTN, which has established clinical trial sites globally and in SA, 
funded the clinical trials in the USA and SA.4 
SAAVI DNA-C2 was based on a mixture of 2 DNA plasmids. 
One plasmid expressed a polyprotein designated Grttn, consisting of 
translational fusions of HIV-1 subtype C Gag, reverse transcriptase, 
Tat and Nef. All the sequences were codon optimised for high levels of 
expression, as well as being modified to ensure that they were safe in 
humans.20 The second plasmid expressed an HIV-1 subtype C truncated 
envelope protein (Env, gp150). The second vaccine, SAAVI MVA-C, 
was based on a modified version of the smallpox virus vaccine called 
modified vaccinia Ankara (MVA), and had matching HIV genes to 
SAAVI DNA-C2. These vaccines were extensively characterised at UCT 
by means of expression studies, investigations of potency and stability, 
and mouse and non-human primate immunogenicity studies.9,10 In 
order to monitor the potency of SAAVI DNA-C2 during a clinical trial, a 
laboratory compliant with the Organisation for Economic Co-operation 
and Development (OECD) principles of good laboratory practice (GLP) 
was established, the only one in an academic setting in SA. 
Table 1. The pipeline of candidate HIV vaccines at the University of Cape Town (shaded area indicates project complete)
Vaccine platforms Shuttle vector Vaccine made Testing: mice
Testing: non-
human primate Clinical trial References
Vaccines for clinical trial – funded by DAIDS (NIH), HVTN and SAAVI
SAAVI DNA-C2 Burgers et al.9,10
SAAVI MVA-C
Late pipeline candidate vaccines* – funded by SAAVI, Lifelab, Poliomyelitis Research Foundation and DAIDS (NIH)
BCG-GAG Chege et al.11
VLP GAG Jaffray et al.,12 
Chege et al.11,13
Discovery projects† – funded by SAAVI, Lifelab, Poliomyelitis Research Foundation and National Research Foundation
VLP multigene Halsey et al.,14 
Pillay et al.15
Novel DNA vector Tanzer et al.16
Lumpy skin disease virus Shen et al.17
Salmonella Chin’ombe et al.18
DAIDS (NIH) = Division of AIDS, National Institutes of Health; HVTN = HIV Vaccine Trials Network; SAAVI = South African AIDS Vaccine Initiative; VLP = virus-like particle.
*Late pipeline products are those where sufficient research has been done to decide if they are suitable candidates for manufacture for clinical trials.
†Discovery projects include novel vaccine concepts where more research is needed to determine if they would be suitable for manufacture for clinical trials.
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Clinical trials for testing UCT-developed vaccines
The first phase I placebo-controlled clinical trial on SAAVI vaccines 
(approved by the FDA, the MCC, Genetically Modified Organisms 
Act Executive Council, Division of AIDS, NIH and local research 
ethics committees) has been undertaken. The trial, called HVTN 
073/SAAVI 102, was to evaluate the safety and immunogenicity 
of SAAVI DNA-C2 vaccine boosted by SAAVI MVA-C vaccine in 
HIV-uninfected healthy vaccinia-naïve adult participants in SA 
and the USA. Forty-eight participants (12 USA, 18 at each of the 
Cape Town and Soweto sites) were randomised to receive either 
vaccine (n=40) or placebo (n=8). Participants received 3 doses 
intramuscularly (IM) of 4 mg of SAAVI DNA-C2 or placebo 28 days 
apart, and 2 doses IM of SAAVI MVA-C at 1.45 x 109 plaque-forming 
units or placebo at 112 days and 140 days after the first vaccination. 
Immunogenicity endpoints were measured at days 126 and 154 (2 
weeks following the first and second MVA vaccinations). HIV-1 
specific CD4+ and CD8+ T-cell responses were measured using a 
validated intracellular cytokine staining (ICS) assay. The vaccine 
regimen was found to be safe and well tolerated. Vaccination with 
this set of HIV vaccines elicited high CD4+ responses and modest 
CD8+ responses. USA participants had an 80% overall CD4+ 
response rate compared with 64% seen in South Africans. For CD8+ 
T-cells expressing interleukin-2 (IL-2) or interferon-gamma (IFN-γ), 
the overall response rate at 126 days was 14% (USA 30%, SA 8%); 
which increased to 33% at 154 days (USA 50%, SA 29%) after the 
second MVA vaccination.21 These data are consistent with other 
prime-boost regimens of DNA and MVA, and suggested further 
study of these subtype C immunogens was warranted. Based on 
the above responses, a study extension was proposed and approved 
in 2011, following the promising results of the RV144 trial which 
will add a protein boost of subtype C gp140 with MF59 (Novartis) 
to the DNA/MVA prime-boost regimen in this study. In addition, 
SAAVI DNA-C2, SAAVI MVA-C and Novartis subtype C gp140 with 
MF59 adjuvant in another phase 1 study, HVTN 086/SAAVI 103 was 
approved and commenced enrolment at the end of 2011.
Conclusions
Two candidate HIV vaccines have successfully been taken from basic 
research concepts through to phase 1 clinical trial. This required the 
establishment of a sophisticated laboratory infrastructure and skill-
sets for the preclinical part of the programme, and the exploitation 
of various networks and of different sets of expertise to successfully 
move the product into clinical trial. In addition a number of other 
candidate HIV vaccines have been developed. The considerable 
expertise and experience gained during the HIV vaccine development 
programme can be used to develop other candidate vaccines in future.
This research represents possibly the best example of a 
multidisciplinary research effort taking a project from the basic 
concept through to clinical trial in Africa. It shows that academic 
institutions in SA have the capacity to undertake these projects, and 
contribute meaningfully to the global initiative to make a successful 
prophylactic HIV vaccine.
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